SEAKER cells coordinate cellular immunotherapy with localized chemotherapy. (October 2022)

• Record Type: Journal Article
• Authors: Lane, Isabel C.; Jan, Max
• Is Part Of: Trends in pharmacological sciences. Volume 43:Number 10(2022)
• Page Start: 804
• Page End: 805
• Publication Date: 2022-10
• Subjects: cell therapy -- synthetic biology; Pharmacology -- Periodicals; Pharmacology -- trends -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Electronic journals; Periodicals; 615.1
• DOI: 10.1016/j.tips.2022.04.001
• Languages: English
• ISSNs: 0165-6147

Abstract

Abstract : Tumor antigen escape and T cell dysfunction limit the effectiveness of chimeric antigen receptor (CAR) T cell therapies. To overcome these challenges, Gardner et al. engineered synthetic enzyme-armed killer (SEAKER) cells to coexpress a CAR and a prodrug-activating enzyme to orchestrate a dual immunologic and pharmacologic attack at the tumor site.